Laryngopharyngeal Reflux (LPR)

Overview

Laryngopharyngeal reflux (LPR) is an inflammatory condition of the throat, voice box, and upper aerodigestive tract caused by the reflux of gastric — and sometimes duodenal — contents beyond the esophagus into the pharynx and larynx (Cui et al., World Journal of Gastroenterology, 2024). First comprehensively described by Koufman in 1991, LPR is now recognized as a condition distinct from gastroesophageal reflux disease (GERD), with different mechanisms, symptom patterns, and treatment considerations (Tsilivigkos et al., European Archives of Oto-Rhino-Laryngology, 2025). It is extremely common in ear, nose, and throat practice, with reflux implicated in over 50% of patients who present with hoarseness or attend an otolaryngology clinic (Gunjawate and Ravi, European Archives of Oto-Rhino-Laryngology, 2025).

The single most important concept in modern LPR care — and the one that separates expert evaluation from empiric guesswork — is the distinction between symptoms and disease. The 2026 San Diego Consensus formalized this: the term laryngopharyngeal symptoms (LPS) applies to aerodigestive symptoms that could be induced by reflux (cough, voice change, throat clearing, excess phlegm, throat pain), while laryngopharyngeal reflux disease (LPRD) is reserved for patients who have those symptoms plus objective evidence of reflux. Critically, the presence of laryngopharyngeal symptoms does not equate to LPRD, and laryngoscopic findings alone cannot diagnose it (Yadlapati et al., American Journal of Gastroenterology, 2026). This matters because LPR differs fundamentally from the typical reflux seen on your other pages: patients tend to reflux while upright rather than lying down, usually have normal esophageal motility, and only uncommonly have visible esophagitis — which is why a normal endoscopy and even a normal esophageal acid study do not exclude the diagnosis (Gunjawate and Ravi, European Archives of Oto-Rhino-Laryngology, 2025). Compounding the challenge, there is currently no universally accepted gold standard for either the diagnosis or the treatment of LPR, which places a premium on a careful, objective, multidisciplinary evaluation (Krause et al., Annals of the New York Academy of Sciences, 2022).

Causes

LPR is caused by the reflux of injurious gastric and duodenal contents into a throat and voice box that — unlike the esophagus — lack robust defenses against acid, pepsin, and bile (Tsilivigkos et al., European Archives of Oto-Rhino-Laryngology, 2025). Several interacting mechanisms explain the symptoms:

• Direct mucosal injury from the refluxate itself. Pepsin (a stomach enzyme) and bile acids damage the delicate pharyngeal and laryngeal lining, and pepsin has been detected in the saliva, sinuses, middle ear, and tears of LPR patients, reflecting how far the refluxate can travel (Tsilivigkos et al., European Archives of Oto-Rhino-Laryngology, 2025).

• Acid, non-acid, and mixed reflux. Unlike typical heartburn, LPR symptoms are frequently driven by weakly acidic or non-acidic reflux, which is a major reason acid-suppressing medication alone often falls short (Lechien et al., Clinical Otolaryngology, 2021).

• A vagally mediated reflex mechanism. Reflux reaching the lower esophagus can trigger reflex throat clearing and coughing through nerve pathways, and that repeated throat clearing and coughing then causes further mechanical injury to the vocal cords in a self-perpetuating cycle (Tsilivigkos et al., European Archives of Oto-Rhino-Laryngology, 2025).

• Dysfunction of the upper esophageal sphincter, the muscular valve that normally protects the throat from reflux (Close, European Journal of Gastroenterology & Hepatology, 2002).

• Laryngeal hypersensitivity and hypervigilance. A hyper-responsive, over-perceiving larynx commonly contributes to symptoms, and in many patients is the dominant driver even when little or no reflux is present (Yadlapati et al., American Journal of Gastroenterology, 2026).

‍

Risk Factors

The risk factors for LPR overlap substantially with those for reflux disease generally (see our GERD / Acid Reflux pillar):

• Obesity and central adiposity, which raise intra-abdominal pressure and reflux burden.

• Hiatal hernia, which weakens the antireflux barrier (see our Hiatal & Paraesophageal Hernia page).

• Dietary factors — acidic foods, caffeine, alcohol, chocolate, fatty and spicy foods, and large or late-night meals (Gunjawate and Ravi, European Archives of Oto-Rhino-Laryngology, 2025).

• Smoking and alcohol use.

• Professional or heavy voice use, which interacts with laryngeal irritation.

• Concurrent GERD, which may coexist with LPR though the two can also occur independently (Tsilivigkos et al., European Archives of Oto-Rhino-Laryngology, 2025).

‍

How Affects the Body

In LPR, refluxed stomach contents reach the pharynx and larynx, where the mucosa lacks the protective mechanisms of the esophagus — there is no equivalent of the esophageal clearance and buffering that normally limits acid and pepsin injury (Tsilivigkos et al., European Archives of Oto-Rhino-Laryngology, 2025). Even brief or small-volume exposure can therefore provoke inflammation, edema, and the characteristic throat symptoms. Pepsin is a central culprit: it can remain on the laryngeal tissue and be reactivated by subsequent acid exposure, producing molecular and morphologic injury and triggering local inflammatory responses (Samuels et al., Annals of the New York Academy of Sciences, 2024). Over time, the combination of chemical injury and the mechanical trauma of chronic throat clearing and coughing produces the laryngeal changes attributed to reflux. A key biological difference from GERD is that LPR is predominantly an upright, daytime phenomenon with normal esophageal motility and little esophagitis, which is precisely why esophagus-focused tests can be normal in a patient who genuinely has reflux reaching the throat (Gunjawate and Ravi, European Archives of Oto-Rhino-Laryngology, 2025). Layered on top of the tissue injury is laryngeal hypersensitivity — a heightened neural perception of normal or minor stimuli — which explains why symptom severity often correlates poorly with the amount of measurable reflux (Yadlapati et al., American Journal of Gastroenterology, 2026).

‍

Complications

Serious, life-threatening complications of LPR are infrequent, but the condition carries real consequences (Chan et al., Neurogastroenterology & Motility, 2026):

• Substantial impairment of quality of life, driven by persistent voice dysfunction, chronic cough, and throat clearing that affect social and work functioning; patients also report high rates of anxiety, depression, and symptom-specific hypervigilance (Chan et al., Neurogastroenterology & Motility, 2026).

• Laryngeal lesions associated with chronic reflux, including contact ulcers, granulomas, vocal cord nodules, reflux laryngitis, and subglottic stenosis (Gunjawate and Ravi, European Archives of Oto-Rhino-Laryngology, 2025).

• An association with laryngeal cancer. In a systematic review and meta-analysis of 18 studies, laryngopharyngeal symptoms were associated with an odds ratio of 3.09 for laryngeal cancer — similar in magnitude to the risk conferred by GERD (odds ratio 2.37) — though this reflects an association, not proof of causation (Chan et al., Neurogastroenterology & Motility, 2026).

• Bronchopulmonary complications such as chronic cough and, in some patients, recurrent aspiration-related problems (Close, European Journal of Gastroenterology & Hepatology, 2002).

‍

Symptoms and Signs

LPR produces upper-aerodigestive symptoms that are often mistaken for sinus, allergy, or primary throat conditions (Gunjawate and Ravi, European Archives of Oto-Rhino-Laryngology, 2025):

• Chronic throat clearing — one of the most common complaints.

• Hoarseness or voice change (dysphonia).

• Globus sensation — the feeling of a lump or something stuck in the throat.

• Chronic cough.

• Excess throat mucus and postnasal-drip sensation.

• Sore or burning throat and throat pain.

• Dysphagia (difficulty swallowing) in some patients.

Importantly, LPR is often called "silent reflux" because many patients have none of the classic heartburn or regurgitation of typical GERD (Tsilivigkos et al., European Archives of Oto-Rhino-Laryngology, 2025). Symptoms are generally considered clinically relevant when they occur at least twice weekly for at least eight weeks (O'Rourke et al., Neurogastroenterology & Motility, 2026). Alarm features — progressive difficulty swallowing, a neck mass, unexplained weight loss, coughing up blood, or persistent hoarseness lasting more than a few weeks (especially in smokers) — require prompt specialist evaluation to exclude malignancy and other serious causes (O'Rourke et al., Neurogastroenterology & Motility, 2026).

‍

Diagnosis

Diagnosing LPR is challenging precisely because symptoms and laryngoscopic findings are nonspecific, and the modern approach emphasizes objective confirmation before long-term treatment (Yadlapati et al., American Journal of Gastroenterology, 2026):

• Clinical history and symptom scoring. Validated tools such as the Reflux Symptom Index help quantify symptom burden and track response, though they are not diagnostic on their own (Krause and Yadlapati, Alimentary Pharmacology & Therapeutics, 2024).

• Flexible laryngoscopy is valuable for assessing the larynx and — critically — for ruling out non-reflux causes of symptoms such as tumors, muscle tension dysphonia, vocal cord lesions, and paresis. However, laryngoscopic signs attributed to reflux have low specificity and poor inter-rater reliability, and laryngoscopic findings alone cannot diagnose LPRD; in one study of 105 asymptomatic volunteers, 86% had findings typically attributed to reflux (Katz et al., ACG Clinical Guideline, 2022).

• Ambulatory reflux monitoring is the key objective test and is required to diagnose LPRD when symptoms are isolated, persist, or when invasive antireflux therapy is being considered. The two recommended modalities are 24-hour pH-impedance monitoring and 96-hour wireless pH monitoring (Yadlapati et al., American Journal of Gastroenterology, 2026). pH-impedance is preferred when there are no typical reflux symptoms because it detects non-acid and weakly acidic reflux and the proximal reach of the refluxate; pH-only catheter monitoring is not recommended for evaluating laryngopharyngeal symptoms (O'Rourke et al., Neurogastroenterology & Motility, 2026).

• Upper endoscopy (EGD) evaluates for esophagitis, Barrett's esophagus, and other esophageal pathology and is part of the workup when LPRD is being formally diagnosed or management escalated (see our Erosive Esophagitis and Barrett's Esophagus pages) (Yadlapati et al., American Journal of Gastroenterology, 2026).

• High-resolution esophageal manometry assesses esophageal motility before any antireflux procedure and excludes motility disorders such as achalasia that can masquerade as reflux (see our Achalasia page) (Kamal et al., Digestive Diseases and Sciences, 2023).

.

Differential Diagnosis

Because LPR symptoms are nonspecific, a broad differential must be considered — and several of these conditions commonly cause the exact symptoms wrongly attributed to reflux (Lechien et al., European Archives of Oto-Rhino-Laryngology, 2026):

• Laryngeal hypersensitivity and functional laryngeal disorders — a hyper-responsive, hypervigilant larynx producing cough, throat clearing, and globus with little or no actual reflux; this is a leading reason acid suppression fails (Yadlapati et al., American Journal of Gastroenterology, 2026).

• Chronic rhinosinusitis and allergic disease, which cause postnasal drip, throat clearing, and cough.

• Tobacco- or irritant-induced laryngitis.

• Muscle tension dysphonia and other primary voice disorders.

• Asthma, chronic bronchitis, and ACE-inhibitor-induced cough.

• Laryngeal or pharyngeal malignancy and benign vocal cord lesions — the critical "cannot-miss" diagnoses that justify laryngoscopy (Katz et al., ACG Clinical Guideline, 2022).

• Typical GERD and its phenotypes — which may coexist with, or be mistaken for, LPR (see our Non-Erosive Reflux Disease and PPI-Refractory GERD pages).

Lifestyle Modifications

Dietary and behavioral changes are a foundational, first-line part of LPR management and are reasonable as an initial step for patients with mild symptoms even before medication (Kamal et al., Digestive Diseases and Sciences, 2023):

• Weight loss in overweight and obese patients.

• Avoiding dietary triggers — acidic foods, caffeine, alcohol, chocolate, fatty and spicy foods (Gunjawate and Ravi, European Archives of Oto-Rhino-Laryngology, 2025).

• Avoiding late-night meals and not lying down soon after eating; elevating the head of the bed for nighttime symptoms.

• Smoking cessation and reducing alcohol.

• Vocal hygiene and hydration to reduce the mechanical trauma of throat clearing.

• Stress reduction, given the prominent role of hypervigilance and affective factors in symptom perception (Chan et al., Neurogastroenterology & Motility, 2026).

Robust studies isolating the effect of diet alone are limited, so lifestyle change is best used as part of a comprehensive plan rather than as a stand-alone cure (Gunjawate and Ravi, European Archives of Oto-Rhino-Laryngology, 2025).

‍

Treatment Options

Treatment of LPR is stepwise, and — because response rates are variable and no gold-standard therapy exists — should be matched to whether reflux has actually been confirmed and to the type of reflux present (Krause et al., Annals of the New York Academy of Sciences, 2022).

Medical therapy:

• Proton pump inhibitors (PPIs) are the conventional first-line medication and are most appropriate when typical reflux symptoms coexist or when acid reflux has been objectively confirmed. They should be dosed 30–60 minutes before meals (Kamal et al., Digestive Diseases and Sciences, 2023). It is important to counsel patients honestly: evidence for the superiority of PPIs over placebo in LPR is limited and inconsistent, in large part because many "LPR" patients actually have non-acid reflux or laryngeal hypersensitivity that acid suppression cannot address (Lechien et al., European Archives of Oto-Rhino-Laryngology, 2026).

• Alginates form a physical raft that limits reflux reaching the throat and are a useful option, including for non-acid reflux and as a way to avoid rebound when weaning off a PPI (Tsilivigkos et al., European Archives of Oto-Rhino-Laryngology, 2025).

• H2-receptor antagonists, magaldrate, and baclofen are additional or adjunctive options, with baclofen aimed at reducing transient lower-esophageal-sphincter relaxations (Krause et al., Annals of the New York Academy of Sciences, 2022).

• Personalized, reflux-type-directed therapy. When pH-impedance testing characterizes reflux as acid, non-acid, or mixed, treatment can be tailored accordingly — PPIs for acid-predominant disease and alginate/magaldrate strategies for non-acid disease — an approach shown to improve outcomes (Lechien et al., Clinical Otolaryngology, 2021).

• Neuromodulators and behavioral/laryngeal recalibration therapy are central when laryngeal hypersensitivity and hypervigilance drive symptoms, and are responsive even when reflux is minimal (Yadlapati et al., American Journal of Gastroenterology, 2026).

Procedural and surgical therapy (reserved for objectively confirmed, refractory disease):

• Laparoscopic or robotic antireflux surgery (fundoplication) may benefit carefully selected patients with objectively documented reflux whose symptoms are recalcitrant to medical therapy. Patient selection is paramount: before considering fundoplication for LPR symptoms in the absence of GERD, an otolaryngologic evaluation is warranted to exclude non-reflux causes, and a thorough pre-procedure assessment of esophageal function is essential (see our antireflux surgery and Nissen Fundoplication pages) (Kamal et al., Digestive Diseases and Sciences, 2023).

• Magnetic sphincter augmentation (LINX) and transoral incisionless fundoplication (TIF) are additional options in appropriately selected patients, though patients should be counseled that the efficacy of endoscopic treatments specifically for LPR is not completely established (see our LINX and TIF pages) (Kamal et al., Digestive Diseases and Sciences, 2023).

‍

Evaluation is warranted for throat symptoms — chronic throat clearing, hoarseness, globus, cough, or excess mucus — that persist at least twice weekly for eight weeks or more, particularly when they do not improve with simple measures (O'Rourke et al., Neurogastroenterology & Motility, 2026). Prompt specialist evaluation is needed for any alarm feature: persistent hoarseness beyond a few weeks (especially in a smoker), progressive difficulty swallowing, a neck mass, coughing up blood, or unintentional weight loss — all of which require laryngoscopy and, when indicated, imaging to exclude malignancy before symptoms are attributed to reflux (O'Rourke et al., Neurogastroenterology & Motility, 2026).

‍

When to Seek Treatment

Referral for a dedicated, multidisciplinary reflux evaluation is appropriate when laryngopharyngeal symptoms are isolated (no typical heartburn or regurgitation), when they persist despite an empiric trial of lifestyle change and acid suppression, or when invasive antireflux therapy is being contemplated — all situations in which objective reflux monitoring is required rather than optional (Yadlapati et al., American Journal of Gastroenterology, 2026). Because surgical and endoscopic outcomes in LPR depend so heavily on correct patient selection and on excluding non-reflux causes, referral should be to a program that integrates gastroenterology, otolaryngology, and foregut surgery and that completes endoscopy, ambulatory reflux monitoring, and manometry before recommending any procedure (Kamal et al., Digestive Diseases and Sciences, 2023).

‍

Long-Term Outlook

Most patients with LPR can achieve meaningful symptom control, but because a substantial share follow a recurrent or chronic course, a durable, mechanism-based long-term plan matters more than any single course of medication (Lechien et al., The Laryngoscope, 2023). For patients with confirmed acid-driven reflux, the lowest effective dose of acid suppression — often combined with alginates and sustained lifestyle change — provides control while minimizing medication exposure (Kamal et al., Digestive Diseases and Sciences, 2023). For patients whose symptoms stem from non-acid reflux or laryngeal hypersensitivity, the long-term outlook depends on alginate-based and neuromodulatory/behavioral strategies rather than escalating acid suppression (Yadlapati et al., American Journal of Gastroenterology, 2026). The patients who benefit most from a definitive antireflux procedure are precisely those in whom testing has proven reflux and excluded non-reflux causes — which is why an integrated foregut-and-airway program that phenotypes the disease accurately, manages weight and lifestyle, and matches therapy to the true mechanism produces the best long-term results (see our GERD / Acid Reflux pillar).

‍

Prognosis

The prognosis of LPR is generally favorable in that life-threatening long-term sequelae are infrequent, though the condition is often protracted and can significantly affect quality of life (Chan et al., Neurogastroenterology & Motility, 2026). The clinical course varies: in a prospective study of patients with objectively diagnosed LPR followed for three years, roughly 29% had acute (non-recurring) disease, 41% had recurrent disease, and 30% followed a chronic course, with higher baseline symptom scores predicting a recurrent or chronic trajectory (Lechien et al., The Laryngoscope, 2023). Patients with acute disease improve faster with treatment than those with recurrent or chronic disease (Lechien et al., The Laryngoscope, 2023). Outcomes are best when the diagnosis is objectively confirmed, the reflux type is characterized, and any contribution from laryngeal hypersensitivity is addressed — because treating the wrong mechanism (for example, escalating acid suppression in a patient whose symptoms are driven by a hypersensitive larynx) leads to persistent symptoms and dissatisfaction (Yadlapati et al., American Journal of Gastroenterology, 2026).

‍

WhyChoose Dr. de la Cruz-Muñoz

Laryngopharyngeal reflux is one of the most over-diagnosed and mismanaged conditions in all of reflux care — patients are routinely placed on escalating, long-term acid suppression based on nonspecific throat symptoms and laryngoscopy findings alone, when the modern standard requires objective proof of reflux and exclusion of non-reflux causes before committing to long-term medication or surgery. Dr. Nestor de la Cruz-Muñoz, MD, FACS, DABOM, is a board-certified minimally invasive foregut and bariatric surgeon in Miami with extensive experience across the full spectrum of antireflux therapy — laparoscopic and robotic fundoplication, magnetic sphincter augmentation (LINX), transoral incisionless fundoplication (TIF), hiatal and paraesophageal hernia repair, and Roux-en-Y gastric bypass as an antireflux operation. His practice insists on complete, objective evaluation — endoscopy, ambulatory pH-impedance monitoring, and high-resolution manometry, in coordination with otolaryngology — so that true laryngopharyngeal reflux disease is distinguished from laryngeal hypersensitivity and non-reflux throat conditions, malignancy is never missed, and the patients most likely to benefit from a procedure are precisely the ones selected for it. Patients benefit from an integrated, multidisciplinary foregut-and-airway program, evidence-based medical management, and structured long-term follow-up.

‍